New drug combo trial offers hope for Tough-to-Treat blood disorder
NCT ID NCT02530463
Summary
This study is testing whether combining two immunotherapy drugs (nivolumab and ipilimumab) with a chemotherapy drug (azacitidine) is safe and effective for treating myelodysplastic syndromes (MDS), a type of blood and bone marrow cancer. It is for 99 patients, including those newly diagnosed and those whose disease has returned after prior treatment. The goal is to see if this combination can better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.